CYP19A1 and cancer: Palbociclib (Figure 5) is a selective inhibitor of CDK4 and CDK6 and it was the first inhibitor of CDKs that was approved as a cancer therapy in combination with letrozole, an aromatase inhibitor (Lu, 2015; Turner et al., 2015; Finn et al., 2016).